Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer

Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation

(2011) U. Bharadwaj et al.   CARCINOGENESIS

Mesothelin expression correlates with prolonged patient survival in gastric cancer

(2011) Kenji Baba et al.   JOURNAL OF SURGICAL ONCOLOGY

Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression

(2011) Uddalak Bharadwaj et al.   Molecular Cancer

Co-Expression of Mesothelin and CA125 Correlates With Unfavorable Patient Outcome in Pancreatic Ductal Adenocarcinoma

(2011) Takahiro Einama et al.   PANCREAS

Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway

(2009) Ming-Cheng Chang et al.   BIOCHEMICAL JOURNAL

High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma

(2009) W-F Cheng et al.   BRITISH JOURNAL OF CANCER

Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo

(2009) Koichi Inami et al.   CANCER SCIENCE

Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

(2009) Raffit Hassan et al.   LUNG CANCER

Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3

(2008) U. Bharadwaj et al.   MOLECULAR CANCER RESEARCH

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

(2008) M. Li et al.   MOLECULAR CANCER THERAPEUTICS

Mesothelin targeted cancer immunotherapy

(2007) Raffit Hassan et al.   EUROPEAN JOURNAL OF CANCER